This is to inform you that the Board of Directors of the Company at its meeting held on June 17 2022 has approved the acquisition of 51% equity shares in GLS Pharma Limited operating in oncology business and having manufacturing facility in Hyderabad for a total consideration of INR 28 05 00 000. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Part A of Schedule III of the aforesaid regulations is attached as Annexure A.
Aurobindo Pharma: Announcement under Regulation 30 (LODR)-Acquisition
June 18, 2022
Download PDF
Aurobindo Pharma
Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.
Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month